The Heart -- The US labeling for clopidogrel (Plavix, Sanofi-Aventis/Bristol-Myers Squibb) has been updated to include additional information on factors affecting patients’ responses to the drug. This includes a large new section on pharmacogenetics and new advice that concomitant use of drugs that inhibit the CYP2C19 enzyme, such as omeprazole, should be discouraged.
